Spending on GLP-1 drugs under the Medicare Part D program has increased dramatically in recent years, and the annual cost of these drugs in the United States  – upwards of $11,000 at recent list prices – has raised concerns about the fiscal impact of broad coverage of GLP-1 drugs on Medicare, other health insurers and patients, a KFF analysis finds.